ArticleJournal of hematology & oncology2019

Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.

Yongkun Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.